Cargando…

Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period

Background: Hemochromatosis is a genetic condition of iron overload caused by deficiency of hepcidin. In a previous stage of this study, patients with suspected hemochromatosis had their quality of life (QL) measured. We observed that QL scores differed among genotypic groups of patients. In this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Acevedo, Luis Alfredo Utria, Alvarenga, Aline Morgan, Fonseca, Paula Fernanda Silva, da Silva, Nathália Kozikas, Cançado, Rodolfo Delfini, Naoum, Flavio Augusto, Dinardo, Carla Luana, Pereira, Alexandre Costa, Brissot, Pierre, Santos, Paulo Caleb Junior Lima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774363/
https://www.ncbi.nlm.nih.gov/pubmed/35052458
http://dx.doi.org/10.3390/genes13010118
_version_ 1784636323786653696
author Acevedo, Luis Alfredo Utria
Alvarenga, Aline Morgan
Fonseca, Paula Fernanda Silva
da Silva, Nathália Kozikas
Cançado, Rodolfo Delfini
Naoum, Flavio Augusto
Dinardo, Carla Luana
Pereira, Alexandre Costa
Brissot, Pierre
Santos, Paulo Caleb Junior Lima
author_facet Acevedo, Luis Alfredo Utria
Alvarenga, Aline Morgan
Fonseca, Paula Fernanda Silva
da Silva, Nathália Kozikas
Cançado, Rodolfo Delfini
Naoum, Flavio Augusto
Dinardo, Carla Luana
Pereira, Alexandre Costa
Brissot, Pierre
Santos, Paulo Caleb Junior Lima
author_sort Acevedo, Luis Alfredo Utria
collection PubMed
description Background: Hemochromatosis is a genetic condition of iron overload caused by deficiency of hepcidin. In a previous stage of this study, patients with suspected hemochromatosis had their quality of life (QL) measured. We observed that QL scores differed among genotypic groups of patients. In this reported final phase of the study, the aims were to compare QL scores after a treatment period of approximately 3 years and to analyze a possible association of the serum ferritin values with QL scores. Methods: Sixty-five patients were enrolled in this final phase and divided into group 1 (patients that showed primary iron overload and homozygous genotype for the HFE p.Cys282Tyr mutation) and group 2 (other kinds of genotypes). Short Form 36 (SF-36) was performed and consisted of eight domains with a physical and also a mental component. Results: Both groups had a significant decrease in serum ferritin concentrations: group 1 had a variation from 1844 ± 1313 ng/mL to 281 ± 294 ng/mL, and group 2 had a variation from 1216 ± 631 ng/mL to 236 ± 174 ng/mL. Group 1 had a smaller mean value for these six SF-36 domains compared with group 2, indicating a worse QL. Conclusions: In this final stage, six domains demonstrated a difference among genotypic groups (role emotional and mental health, adding to the four of the initial phase), reassuring the impact of the identified genotype on the QL of hemochromatosis patients. Furthermore, despite that both patient groups demonstrated similar and significant decreases in serum ferritin values, no association was found between the decrease in this biological parameter and the SF-36 domains.
format Online
Article
Text
id pubmed-8774363
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87743632022-01-21 Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period Acevedo, Luis Alfredo Utria Alvarenga, Aline Morgan Fonseca, Paula Fernanda Silva da Silva, Nathália Kozikas Cançado, Rodolfo Delfini Naoum, Flavio Augusto Dinardo, Carla Luana Pereira, Alexandre Costa Brissot, Pierre Santos, Paulo Caleb Junior Lima Genes (Basel) Article Background: Hemochromatosis is a genetic condition of iron overload caused by deficiency of hepcidin. In a previous stage of this study, patients with suspected hemochromatosis had their quality of life (QL) measured. We observed that QL scores differed among genotypic groups of patients. In this reported final phase of the study, the aims were to compare QL scores after a treatment period of approximately 3 years and to analyze a possible association of the serum ferritin values with QL scores. Methods: Sixty-five patients were enrolled in this final phase and divided into group 1 (patients that showed primary iron overload and homozygous genotype for the HFE p.Cys282Tyr mutation) and group 2 (other kinds of genotypes). Short Form 36 (SF-36) was performed and consisted of eight domains with a physical and also a mental component. Results: Both groups had a significant decrease in serum ferritin concentrations: group 1 had a variation from 1844 ± 1313 ng/mL to 281 ± 294 ng/mL, and group 2 had a variation from 1216 ± 631 ng/mL to 236 ± 174 ng/mL. Group 1 had a smaller mean value for these six SF-36 domains compared with group 2, indicating a worse QL. Conclusions: In this final stage, six domains demonstrated a difference among genotypic groups (role emotional and mental health, adding to the four of the initial phase), reassuring the impact of the identified genotype on the QL of hemochromatosis patients. Furthermore, despite that both patient groups demonstrated similar and significant decreases in serum ferritin values, no association was found between the decrease in this biological parameter and the SF-36 domains. MDPI 2022-01-10 /pmc/articles/PMC8774363/ /pubmed/35052458 http://dx.doi.org/10.3390/genes13010118 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Acevedo, Luis Alfredo Utria
Alvarenga, Aline Morgan
Fonseca, Paula Fernanda Silva
da Silva, Nathália Kozikas
Cançado, Rodolfo Delfini
Naoum, Flavio Augusto
Dinardo, Carla Luana
Pereira, Alexandre Costa
Brissot, Pierre
Santos, Paulo Caleb Junior Lima
Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period
title Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period
title_full Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period
title_fullStr Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period
title_full_unstemmed Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period
title_short Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period
title_sort quality of life scores remained different among the genotypic groups of patients with suspected hemochromatosis, even after treatment period
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774363/
https://www.ncbi.nlm.nih.gov/pubmed/35052458
http://dx.doi.org/10.3390/genes13010118
work_keys_str_mv AT acevedoluisalfredoutria qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT alvarengaalinemorgan qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT fonsecapaulafernandasilva qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT dasilvanathaliakozikas qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT cancadorodolfodelfini qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT naoumflavioaugusto qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT dinardocarlaluana qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT pereiraalexandrecosta qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT brissotpierre qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod
AT santospaulocalebjuniorlima qualityoflifescoresremaineddifferentamongthegenotypicgroupsofpatientswithsuspectedhemochromatosisevenaftertreatmentperiod